Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 879-883

  Sotgiu, Giovanni ^a   Lange, Christoph ^b   Richardson, Morgan D'Arcy ^c   Matteelli, Alberto ^d   Centis, Rosella ^e   Eker, Barbara ^b   Guenther, Gunar ^b   Spanevello, Antonio ^f   Migliori, Giovanni Battista ^e  

^a UNIVERSITY OF SASSARI   (Italy)

^b RESEARCH CENTER BORSTEL   (Germany)

^c PATH   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e IRCCS   (Italy)

^f UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Adverse events; MDR TB; XDR TB

Indexed keywords

LINEZOLID;

DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LEUKOPENIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; PERIPHERAL NEUROPATHY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; OXAZOLIDINONES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 70349451253     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp265     Document Type: Note

References (6)

1. Koh WJ, Kwon OJ, Gwak H et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64 388-91.
2. Eker B, Ortmann J, Migliori GB et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14 1700-6.
3. Migliori GB, Eker B, Richardson MD et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in MDR-TB. Eur Respir J 2009; doi:10.1183/09031936.00009509.
4. World Health Organization. Global Tuberculosis Control 2008, Surveillance, Planning, Financing: WHO Report 2008. WHO/HTM/TB2008.393 Geneva: World Health Organization, 2008.
5. Laserson K, Thorpe LE, Leimane V et al. Speaking the same language: Treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-5.
6. Sotgiu G, Ferrara G, Matteelli A et al. Epidemiology and clinical management of XDR-TB: A systematic review by TBNET. Eur Respir J 2009; 33: 871-81.